The information collection updates the standards for FDA acceptance of data from clinical investigations conducted outside the United States and helps ensure the protection of human subjects and the quality and integrity of data obtained from these investigations. We are also amending the investigational device exemption (IDE) and premarket notification (510(k)) regulations to address the requirements for FDA acceptance of data from clinical investigations conducted inside the United States. The amendments are intended to provide consistency in FDA requirements for acceptance of clinical data, whatever the application or submission type.
The information collection includes additional maintenance, retention, and submission of documents indicating (1) clinical investigations conducted outside the United States and used to support IDE or device marketing applications or submissions are conducted in accordance with good clinical practice (GCP), and (2) availability of data for FDA inspection, if deemed necessary.
The information allows reviewers to assess the appropriateness and adequacy of the clinical investigation design, data collection plans, conduct, and performance, and helps to protect human subjects participating in medical device clinical investigations.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.